Background: Lung cancer continues to be the leading cause of cancer-related mortality in the European Union (EU) and deaths from lung cancer have been projected to escalate to epidemic proportions amongst females over the next years. We examined lung cancer mortality rates in men and women from Andalusia (Spain) over a 37-year period [1975-2012].
Methods: Longitudinal epidemiological study analyzing lung cancer mortality trends in males and females. Data on lung cancer mortality in Andalusia for the period 1975-2012 were obtained from the official cause-of-death publications of the Institute of Statistics of Andalusia. For each sex, age-standardized (European standard population) mortality rates (ASR) from lung cancer were calculated for all ages and truncated at 30-64, 65-74, and >75 years using the direct method. Standardized rate trends by age and sex were estimated by joinpoint regression analysis.
Results: In men, the ASR steadily increased through the period 1993-1995, reaching a peak of 145.72 deaths/100,000 people. Subsequently, lung cancer deaths decreased to a rate of 125.47 in the 2011-2012 period. A moderate increase was seen in women until the late 1990s and early 2000s. Thereafter, a very notable rise was observed in females for all age groups, the only exception being older subjects. The sex differences decreased from 8.6:1 in the 1975-1977 period to 6.8:1 in the 2011-2012 period.
Conclusions: Lung cancer mortality rates decreased significantly in Andalusian men from 1975 to 2012. More importantly, we demonstrate for the first time the beginning of the lung cancer epidemics in Andalusian women as previously predicted for this area.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283328 | PMC |
http://dx.doi.org/10.3978/j.issn.2072-1439.2014.10.28 | DOI Listing |
Trends Pharmacol Sci
January 2025
Department of Surgery, University of California, San Francisco, San Francisco, CA, USA; Center for Bioengineering and Tissue Regeneration, University of California, San Francisco, San Francisco, CA, USA; UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; Department of Radiation Oncology, Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, CA, USA.
Fibrosis accounts for approximately one-third of disease-related deaths globally. Current therapies fail to cure fibrosis, emphasizing the need to identify new antifibrotic approaches. Fibrosis is defined by the excessive accumulation of extracellular matrix (ECM) and resultant stiffening of tissue stroma.
View Article and Find Full Text PDFClin Lung Cancer
December 2024
Department of Thoracic Surgery, Liverpool Heart and Lung Hospital, Liverpool, UK.
Background: To evaluate the real-world surgical and pathological outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre national cohort of patients.
Methods: Retrospective analysis on consecutive patients treated in three tertiary referral hospitals in UK with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB nonsmall cell lung cancer (March 2023-May 2024). Surgical and pathological outcomes were assessed.
Clin Lung Cancer
December 2024
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Objective: To determine the association between concurrent statin use with immune checkpoint inhibitors (ICIs) and lung cancer-specific and overall mortality in patients with nonsmall cell lung cancer (NSCLC).
Materials And Methods: SEER-Medicare was used to conduct a retrospective study of Medicare beneficiaries ≥65 years of age diagnosed with NSCLC between 2007 and 2017 treated with an ICI. Patients were followed from date of first ICI claim until death, 1 month from last ICI claim, or 12/31/2018, whichever came first.
Clin Lung Cancer
December 2024
Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address:
Eur J Cancer
January 2025
Department of Respiratory Medicine, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-city, Nagano 385-0051, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!